Publications
Pirnay JP, Djebara S, Steurs G, Griselain J, Cochez C, De Soir S, Glonti T, Spiessens A, Vanden Berghe E, Green S, Wagemans J, Lood C, Schrevens E, Chanishvili N, Kutateladze M, de Jode M, Ceyssens PJ, Draye JP, Verbeken G, De Vos D, Rose T, Onsea J, Van Nieuwenhuyse B; Bacteriophage Therapy Providers; Bacteriophage Donors; Soentjens P, Lavigne R, Merabishvili M. Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study. Nat Microbiol. 2024 Jun;9(6):1434-1453. doi: 10.1038/s41564-024-01705-x. Epub 2024 Jun 4. PMID: 38834776; PMCID: PMC11153159.
Pirnay JP, Merabishvili M, De Vos D, Verbeken G. Bacteriophage Production in Compliance with Regulatory Requirements. Methods Mol Biol. 2024;2734:89-115. doi: 10.1007/978-1-0716-3523-0_6. PMID: 38066364.
Pirnay JP, Verbeken G. Magistral Phage Preparations: Is This the Model for Everyone? Clin Infect Dis. 2023 Nov 2;77(Suppl 5):S360-S369. doi: 10.1093/cid/ciad481. PMID: 37932120.
Verbeken G, Pirnay JP. European regulatory aspects of phage therapy: magistral phage preparations. Curr Opin Virol. 2022 Feb;52:24-29. doi: 10.1016/j.coviro.2021.11.005. Epub 2021 Nov 23. PMID: 34801778.
Fauconnier A, Nagel TE, Fauconnier C, Verbeken G, De Vos D, Merabishvili M, Pirnay JP. The Unique Role That WHO Could Play in Implementing Phage Therapy to Combat the Global Antibiotic Resistance Crisis. Front Microbiol. 2020 Sep 3;11:1982. doi: 10.3389/fmicb.2020.01982. PMID: 33013742; PMCID: PMC7500132.
Rohde C, Resch G, Pirnay JP, Blasdel BG, Debarbieux L, Gelman D, Górski A, Hazan R, Huys I, Kakabadze E, Łobocka M, Maestri A, Almeida GMF, Makalatia K, Malik DJ, Mašlaňová I, Merabishvili M, Pantucek R, Rose T, Štveráková D, Van Raemdonck H, Verbeken G, Chanishvili N. Expert Opinion on Three Phage Therapy Related Topics: Bacterial Phage Resistance, Phage Training and Prophages in Bacterial Production Strains. Viruses. 2018 Apr 5;10(4):178. doi: 10.3390/v10040178. PMID: 29621199; PMCID: PMC5923472.
Pirnay JP, Verbeken G, Ceyssens PJ, Huys I, De Vos D, Ameloot C, Fauconnier A. The Magistral Phage. Viruses. 2018 Feb 6;10(2):64. doi: 10.3390/v10020064. PMID: 29415431; PMCID: PMC5850371.
Pirnay JP, Merabishvili M, Van Raemdonck H, De Vos D, Verbeken G. Bacteriophage Production in Compliance with Regulatory Requirements. Methods Mol Biol. 2018;1693:233-252. doi: 10.1007/978-1-4939-7395-8_18. PMID: 29119444.
Jennes S, Merabishvili M, Soentjens P, Pang KW, Rose T, Keersebilck E, Soete O, François PM, Teodorescu S, Verween G, Verbeken G, De Vos D, Pirnay JP. Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury-a case report. Crit Care. 2017 Jun 4;21(1):129. doi: 10.1186/s13054-017-1709-y. PMID: 28583189; PMCID: PMC5460490.
Verbeken G, Huys I, Ceulemans C, Jennes S, De Vos D, Pirnay JP. Bacteriophage therapy: Fast-forward to the past lessons identified from the advanced therapy regulation. Burns. 2016 Feb;42(1):11-12. doi: 10.1016/j.burns.2015.10.022. Epub 2015 Dec 17. PMID: 26702564.
Verbeken G, Huys I, De Vos D, De Coninck A, Roseeuw D, Kets E, Vanderkelen A, Draye JP, Rose T, Jennes S, Ceulemans C, Pirnay JP. Access to bacteriophage therapy: discouraging experiences from the human cell and tissue legal framework. FEMS Microbiol Lett. 2016 Feb;363(4):fnv241. doi: 10.1093/femsle/fnv241. Epub 2015 Dec 16. PMID: 26678555.
Debarbieux L, Pirnay JP, Verbeken G, De Vos D, Merabishvili M, Huys I, Patey O, Schoonjans D, Vaneechoutte M, Zizi M, Rohde C. A bacteriophage journey at the European Medicines Agency. FEMS Microbiol Lett. 2016 Jan;363(2):fnv225. doi: 10.1093/femsle/fnv225. Epub 2015 Dec 10. PMID: 26656541; PMCID: PMC5812529.
Pirnay JP, Blasdel BG, Bretaudeau L, Buckling A, Chanishvili N, Clark JR, Corte-Real S, Debarbieux L, Dublanchet A, De Vos D, Gabard J, Garcia M, Goderdzishvili M, Górski A, Hardcastle J, Huys I, Kutter E, Lavigne R, Merabishvili M, Olchawa E, Parikka KJ, Patey O, Pouilot F, Resch G, Rohde C, Scheres J, Skurnik M, Vaneechoutte M, Van Parys L, Verbeken G, Zizi M, Van den Eede G. Quality and safety requirements for sustainable phage therapy products. Pharm Res. 2015 Jul;32(7):2173-9. doi: 10.1007/s11095-014-1617-7. Epub 2015 Jan 14. PMID: 25585954; PMCID: PMC4452253.
Rose T, Verbeken G, Vos DD, Merabishvili M, Vaneechoutte M, Lavigne R, Jennes S, Zizi M, Pirnay JP. Experimental phage therapy of burn wound infection: difficult first steps. Int J Burns Trauma. 2014 Oct 26;4(2):66-73. PMID: 25356373; PMCID: PMC4212884.
Verbeken G, Huys I, Pirnay JP, Jennes S, Chanishvili N, Scheres J, Górski A, De Vos D, Ceulemans C. Taking bacteriophage therapy seriously: a moral argument. Biomed Res Int. 2014;2014:621316. doi: 10.1155/2014/621316. Epub 2014 Apr 29. PMID: 24868534; PMCID: PMC4020481.
Verbeken G, Pirnay JP, Lavigne R, Jennes S, De Vos D, Casteels M, Huys I. Call for a dedicated European legal framework for bacteriophage therapy. Arch Immunol Ther Exp (Warsz). 2014 Apr;62(2):117-29. doi: 10.1007/s00005-014-0269-y. Epub 2014 Feb 6. PMID: 24500660; PMCID: PMC3950567.
Huys I, Pirnay JP, Lavigne R, Jennes S, De Vos D, Casteels M, Verbeken G. Paving a regulatory pathway for phage therapy. Europe should muster the resources to financially, technically and legally support the introduction of phage therapy. EMBO Rep. 2013 Nov;14(11):951-4. doi: 10.1038/embor.2013.163. Epub 2013 Oct 18. PMID: 24136414; PMCID: PMC3818076.
Huys I, Vaneechoutte M, Verbeken G, Debarbieux L. Key issues in phage therapy: a report of a dedicated workshop at the Viruses of Microbes II meeting. Res Microbiol. 2013 Sep;164(7):806-10. doi: 10.1016/j.resmic.2013.03.020. Epub 2013 Apr 11. PMID: 23583722.
Verbeken G, Pirnay JP, De Vos D, Jennes S, Zizi M, Lavigne R, Casteels M, Huys I. Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine. Arch Immunol Ther Exp (Warsz). 2012 Jun;60(3):161-72. doi: 10.1007/s00005-012-0175-0. Epub 2012 Apr 17. PMID: 22527355.
Pirnay JP, De Vos D, Verbeken G, Merabishvili M, Chanishvili N, Vaneechoutte M, Zizi M, Laire G, Lavigne R, Huys I, Van den Mooter G, Buckling A, Debarbieux L, Pouillot F, Azeredo J, Kutter E, Dublanchet A, Górski A, Adamia R. The phage therapy paradigm: prêt-à-porter or sur-mesure? Pharm Res. 2011 Apr;28(4):934-7. doi: 10.1007/s11095-010-0313-5. Epub 2010 Nov 10. PMID: 21063753.
Merabishvili M, Pirnay JP, Verbeken G, Chanishvili N, Tediashvili M, Lashkhi N, Glonti T, Krylov V, Mast J, Van Parys L, Lavigne R, Volckaert G, Mattheus W, Verween G, De Corte P, Rose T, Jennes S, Zizi M, De Vos D, Vaneechoutte M. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One. 2009;4(3):e4944. doi: 10.1371/journal.pone.0004944. Epub 2009 Mar 20. PMID: 19300511.
Verbeken G, De Vos D, Vaneechoutte M, Merabishvili M, Zizi M, Pirnay JP. European regulatory conundrum of phage therapy. Future Microbiol. 2007 Oct;2(5):485-91. doi: 10.2217/17460913.2.5.485. PMID: 17927471.